Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Trump Says Anthropic No Longer Seen as National Security Threat 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
NEW YORK, Dec. 04, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Zafgen, Inc. (Nasdaq:ZFGN) securities between January 12, 2015 and October 16, 2015.
Click here to learn about the case: http://docs.wongesq.com/ZFGN-Info-Request-Form-971. There is no cost or obligation to you.
The lawsuit alleges that Defendants made misrepresentations about thrombotic adverse events in previous clinical trials of its anti-obesity drug, and leading drug candidate, beloranib. Until October 16, 2015, Zafgen had disclosed only two thrombotic adverse events in one prior clinical trial.
On October 14, 2015, Zafgen issued a statement acknowledging the death of a patient in its ongoing Phase 3 study of beloranib. On October 15, 2015, the Food and Drug Administration informed Zafgen that beloranib had been placed on partial clinical hold. Then on October 16, 2015, Zafgen announced that: (i) the patient who died was receiving beloranib – not a placebo; and (ii) there had been four thrombotic adverse events in prior clinical studies of beloranib – two more than previously reported – as well as two additional, previously undisclosed thrombotic events in ongoing studies.
If you suffered a loss in Zafgen you have until December 21, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/ZFGN-Info-Request-Form-971.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
